{"id":63575,"date":"2026-04-20T21:00:19","date_gmt":"2026-04-20T13:00:19","guid":{"rendered":"https:\/\/flcube.com\/?p=63575"},"modified":"2026-04-20T21:00:20","modified_gmt":"2026-04-20T13:00:20","slug":"sino-biopharmaceuticals-subsidiary-chia-tai-tianqing-secures-nmpa-approval-for-benmelstobart-anlotinib-combo-in-alveolar-soft-part-sarcoma-72-4-orr-and-unreached-median-pfs-in-rare-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63575","title":{"rendered":"Sino Biopharmaceutical&#8217;s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma \u2013 72.4% ORR and Unreached Median PFS in Rare Cancer Indication"},"content":{"rendered":"\n<p>The <strong>National Medical Products Administration<\/strong> (NMPA) has granted approval to <strong>Chia Tai Tianqing Pharmaceutical Co., Ltd.<\/strong>, a wholly-owned subsidiary of <strong>Sino Biopharmaceutical Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG: 1177<\/a>), for the combination of <strong>benmelstobart<\/strong> (anti-PD-L1 monoclonal antibody) and <strong>anlotinib<\/strong> (oral multi-target kinase inhibitor) in the treatment of <strong>advanced or unresectable alveolar soft part sarcoma<\/strong> (ASPS). The approval, supported by the <strong>TQB2450-Ib-02 study<\/strong> showing a <strong>72.41% objective response rate<\/strong> (ORR) and <strong>unreached median progression-free survival<\/strong> (PFS) after 24.9 months of follow-up, follows <strong>Breakthrough Therapy Designation<\/strong> and <strong>Priority Review status<\/strong>, marking the combo&#8217;s fourth approved indication in China.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Approval Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Approving Authority<\/strong><\/td><td>National Medical Products Administration (NMPA)<\/td><\/tr><tr><td><strong>Applicant<\/strong><\/td><td>Chia Tai Tianqing Pharmaceutical Co., Ltd.<\/td><\/tr><tr><td><strong>Parent Company<\/strong><\/td><td>Sino Biopharmaceutical Limited (HKG: 1177)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced or unresectable alveolar soft part sarcoma (ASPS)<\/td><\/tr><tr><td><strong>Regulatory Designations<\/strong><\/td><td>Breakthrough Therapy Designation, Priority Review<\/td><\/tr><tr><td><strong>Approval Basis<\/strong><\/td><td>TQB2450-Ib-02 clinical study results<\/td><\/tr><tr><td><strong>Previous Approvals<\/strong><\/td><td>Endometrial cancer, extensive-stage SCLC, first-line renal cell carcinoma<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-results-tqb2450-ib-02-study\">Clinical Trial Results \u2013 TQB2450-Ib-02 Study<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Efficacy Endpoint<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Objective Response Rate<\/strong> (ORR)<\/td><td><strong>72.41%<\/strong><\/td><\/tr><tr><td><strong>Complete Remission<\/strong> (CR) Rate<\/td><td><strong>10.34%<\/strong><\/td><\/tr><tr><td><strong>Median Progression-Free Survival<\/strong> (PFS)<\/td><td><strong>Not reached<\/strong> (after 24.9 months median follow-up)<\/td><\/tr><tr><td><strong>Prior Chemotherapy Impact<\/strong><\/td><td>No significant effect on ORR<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>No new safety risks identified beyond known profiles of individual agents<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Benmelstobart:<\/strong> Anti-programmed death-ligand 1 (PD-L1) monoclonal antibody that enhances anti-tumor immune response<\/li>\n\n\n\n<li><strong>Anlotinib:<\/strong> Oral multi-target tyrosine kinase inhibitor with anti-angiogenic and direct anti-tumor effects<\/li>\n\n\n\n<li><strong>Combination Rationale:<\/strong> Dual mechanism targeting both tumor microenvironment (immune checkpoint inhibition) and tumor vasculature\/signaling pathways (kinase inhibition)<\/li>\n\n\n\n<li><strong>ASPS Context:<\/strong> Rare soft tissue sarcoma affecting primarily young adults, with limited treatment options and poor prognosis with conventional therapies<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-significance-amp-competitive-positioning\">Market Significance &amp; Competitive Positioning<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Strategic Element<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Rare Disease Focus<\/strong><\/td><td>Addresses significant unmet need in ASPS, a condition with no standard effective therapies<\/td><\/tr><tr><td><strong>Portfolio Expansion<\/strong><\/td><td>Fourth indication approval strengthens commercial viability of the benmelstobart-anlotinib combination<\/td><\/tr><tr><td><strong>China Leadership<\/strong><\/td><td>Demonstrates Sino Biopharmaceutical&#8217;s dominance in developing innovative combinations for Chinese patient populations<\/td><\/tr><tr><td><strong>Global Potential<\/strong><\/td><td>Strong efficacy data may support international regulatory submissions for this rare indication<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-implications\">Commercial Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pricing Strategy:<\/strong> Premium pricing expected given breakthrough designation and high unmet need in rare sarcoma<\/li>\n\n\n\n<li><strong>Market Access:<\/strong> Priority review status likely facilitates rapid inclusion in provincial reimbursement lists<\/li>\n\n\n\n<li><strong>Physician Adoption:<\/strong> Established safety profile from previous indications supports rapid uptake in sarcoma specialty centers<\/li>\n\n\n\n<li><strong>Revenue Impact:<\/strong> While ASPS is rare, the approval validates the combination&#8217;s broad applicability across tumor types<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-strategy-amp-future-outlook\">Development Strategy &amp; Future Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Additional Indications:<\/strong> Ongoing trials exploring the combination in other rare tumors and solid malignancies<\/li>\n\n\n\n<li><strong>Biomarker Development:<\/strong> Research into predictive biomarkers to optimize patient selection across indications<\/li>\n\n\n\n<li><strong>International Expansion:<\/strong> Potential partnerships for global development leveraging strong clinical data package<\/li>\n\n\n\n<li><strong>Pipeline Validation:<\/strong> Success reinforces Sino Biopharmaceutical&#8217;s strategy of developing proprietary combinations rather than single-agent approaches<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-industry-context-amp-regulatory-environment\">Industry Context &amp; Regulatory Environment<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Oncology Innovation:<\/strong> Part of broader trend of Chinese pharmaceutical companies developing novel combinations for domestic and global markets<\/li>\n\n\n\n<li><strong>Rare Disease Incentives:<\/strong> Benefits from China&#8217;s evolving regulatory framework that encourages development of therapies for rare conditions<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Limited competition in ASPS space creates opportunity for market leadership despite small patient population<\/li>\n\n\n\n<li><strong>Reimbursement Support:<\/strong> Breakthrough therapy designation typically associated with favorable reimbursement decisions in China<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding commercial performance, market penetration, and development plans. Actual results may differ due to risks including market adoption rates, competitive dynamics, reimbursement decisions, and regulatory developments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The National Medical Products Administration (NMPA) has granted approval to Chia Tai Tianqing Pharmaceutical Co.,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":63576,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[661,29,908,15,313],"class_list":["post-63575","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-chia-tai-tianqing-pharmaceutical","tag-combination-therapy","tag-hkg-1177","tag-product-approvals","tag-sino-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sino Biopharmaceutical&#039;s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma \u2013 72.4% ORR and Unreached Median PFS in Rare Cancer Indication - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The National Medical Products Administration (NMPA) has granted approval to Chia Tai Tianqing Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Sino Biopharmaceutical Limited (HKG: 1177), for the combination of benmelstobart (anti-PD-L1 monoclonal antibody) and anlotinib (oral multi-target kinase inhibitor) in the treatment of advanced or unresectable alveolar soft part sarcoma (ASPS). The approval, supported by the TQB2450-Ib-02 study showing a 72.41% objective response rate (ORR) and unreached median progression-free survival (PFS) after 24.9 months of follow-up, follows Breakthrough Therapy Designation and Priority Review status, marking the combo&#039;s fourth approved indication in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63575\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sino Biopharmaceutical&#039;s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma \u2013 72.4% ORR and Unreached Median PFS in Rare Cancer Indication\" \/>\n<meta property=\"og:description\" content=\"The National Medical Products Administration (NMPA) has granted approval to Chia Tai Tianqing Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Sino Biopharmaceutical Limited (HKG: 1177), for the combination of benmelstobart (anti-PD-L1 monoclonal antibody) and anlotinib (oral multi-target kinase inhibitor) in the treatment of advanced or unresectable alveolar soft part sarcoma (ASPS). The approval, supported by the TQB2450-Ib-02 study showing a 72.41% objective response rate (ORR) and unreached median progression-free survival (PFS) after 24.9 months of follow-up, follows Breakthrough Therapy Designation and Priority Review status, marking the combo&#039;s fourth approved indication in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63575\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-20T13:00:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-20T13:00:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2005.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63575#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63575\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sino Biopharmaceutical&#8217;s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma \u2013 72.4% ORR and Unreached Median PFS in Rare Cancer Indication\",\"datePublished\":\"2026-04-20T13:00:19+00:00\",\"dateModified\":\"2026-04-20T13:00:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63575\"},\"wordCount\":584,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63575#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2005.webp\",\"keywords\":[\"Chia Tai Tianqing Pharmaceutical\",\"Combination therapy\",\"HKG: 1177\",\"Product approvals\",\"Sino Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63575#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63575\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63575\",\"name\":\"Sino Biopharmaceutical's Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma \u2013 72.4% ORR and Unreached Median PFS in Rare Cancer Indication - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63575#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63575#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2005.webp\",\"datePublished\":\"2026-04-20T13:00:19+00:00\",\"dateModified\":\"2026-04-20T13:00:20+00:00\",\"description\":\"The National Medical Products Administration (NMPA) has granted approval to Chia Tai Tianqing Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Sino Biopharmaceutical Limited (HKG: 1177), for the combination of benmelstobart (anti-PD-L1 monoclonal antibody) and anlotinib (oral multi-target kinase inhibitor) in the treatment of advanced or unresectable alveolar soft part sarcoma (ASPS). The approval, supported by the TQB2450-Ib-02 study showing a 72.41% objective response rate (ORR) and unreached median progression-free survival (PFS) after 24.9 months of follow-up, follows Breakthrough Therapy Designation and Priority Review status, marking the combo's fourth approved indication in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63575#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63575\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63575#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2005.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2005.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sino Biopharmaceutical's Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma \u2013 72.4% ORR and Unreached Median PFS in Rare Cancer Indication\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63575#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sino Biopharmaceutical&#8217;s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma \u2013 72.4% ORR and Unreached Median PFS in Rare Cancer Indication\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sino Biopharmaceutical's Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma \u2013 72.4% ORR and Unreached Median PFS in Rare Cancer Indication - Insight, China&#039;s Pharmaceutical Industry","description":"The National Medical Products Administration (NMPA) has granted approval to Chia Tai Tianqing Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Sino Biopharmaceutical Limited (HKG: 1177), for the combination of benmelstobart (anti-PD-L1 monoclonal antibody) and anlotinib (oral multi-target kinase inhibitor) in the treatment of advanced or unresectable alveolar soft part sarcoma (ASPS). The approval, supported by the TQB2450-Ib-02 study showing a 72.41% objective response rate (ORR) and unreached median progression-free survival (PFS) after 24.9 months of follow-up, follows Breakthrough Therapy Designation and Priority Review status, marking the combo's fourth approved indication in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63575","og_locale":"en_US","og_type":"article","og_title":"Sino Biopharmaceutical's Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma \u2013 72.4% ORR and Unreached Median PFS in Rare Cancer Indication","og_description":"The National Medical Products Administration (NMPA) has granted approval to Chia Tai Tianqing Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Sino Biopharmaceutical Limited (HKG: 1177), for the combination of benmelstobart (anti-PD-L1 monoclonal antibody) and anlotinib (oral multi-target kinase inhibitor) in the treatment of advanced or unresectable alveolar soft part sarcoma (ASPS). The approval, supported by the TQB2450-Ib-02 study showing a 72.41% objective response rate (ORR) and unreached median progression-free survival (PFS) after 24.9 months of follow-up, follows Breakthrough Therapy Designation and Priority Review status, marking the combo's fourth approved indication in China.","og_url":"https:\/\/flcube.com\/?p=63575","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-20T13:00:19+00:00","article_modified_time":"2026-04-20T13:00:20+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2005.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63575#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63575"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sino Biopharmaceutical&#8217;s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma \u2013 72.4% ORR and Unreached Median PFS in Rare Cancer Indication","datePublished":"2026-04-20T13:00:19+00:00","dateModified":"2026-04-20T13:00:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63575"},"wordCount":584,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=63575#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2005.webp","keywords":["Chia Tai Tianqing Pharmaceutical","Combination therapy","HKG: 1177","Product approvals","Sino Biopharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63575#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63575","url":"https:\/\/flcube.com\/?p=63575","name":"Sino Biopharmaceutical's Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma \u2013 72.4% ORR and Unreached Median PFS in Rare Cancer Indication - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=63575#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=63575#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2005.webp","datePublished":"2026-04-20T13:00:19+00:00","dateModified":"2026-04-20T13:00:20+00:00","description":"The National Medical Products Administration (NMPA) has granted approval to Chia Tai Tianqing Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Sino Biopharmaceutical Limited (HKG: 1177), for the combination of benmelstobart (anti-PD-L1 monoclonal antibody) and anlotinib (oral multi-target kinase inhibitor) in the treatment of advanced or unresectable alveolar soft part sarcoma (ASPS). The approval, supported by the TQB2450-Ib-02 study showing a 72.41% objective response rate (ORR) and unreached median progression-free survival (PFS) after 24.9 months of follow-up, follows Breakthrough Therapy Designation and Priority Review status, marking the combo's fourth approved indication in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63575#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63575"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=63575#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2005.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2005.webp","width":1080,"height":608,"caption":"Sino Biopharmaceutical's Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma \u2013 72.4% ORR and Unreached Median PFS in Rare Cancer Indication"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63575#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sino Biopharmaceutical&#8217;s Subsidiary Chia Tai Tianqing Secures NMPA Approval for Benmelstobart-Anlotinib Combo in Alveolar Soft Part Sarcoma \u2013 72.4% ORR and Unreached Median PFS in Rare Cancer Indication"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2005.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63575","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63575"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63575\/revisions"}],"predecessor-version":[{"id":63577,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63575\/revisions\/63577"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/63576"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63575"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63575"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63575"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}